BeiGene
BeiGene, Ltd.
| Type | Public |
|---|---|
| Traded as | NASDAQ: BGNE , Template:HKEX |
| Key people | John V. Oyler (CEO) |
| Industry | Biotechnology |
| Products | Cancer treatments |
BeiGene, Ltd. is a global, commercial-stage biotechnology company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company was founded in 2010 by John V. Oyler and Xiaodong Wang and is headquartered in Beijing, China.
History[edit]
BeiGene was established in 2010 with the aim of creating a world-class biotechnology company in China. The company has since expanded its operations globally, with offices and facilities in the United States, Australia, and various other countries.
Research and Development[edit]
BeiGene's research and development efforts are primarily focused on oncology. The company has a broad pipeline of drug candidates, including both small molecules and biologics. Key areas of research include immuno-oncology, molecularly targeted therapy, and combination therapy.
Products[edit]
BeiGene has developed several drug candidates that are in various stages of clinical development. Some of the notable products include:
- Brukinsa (zanubrutinib): A Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma and other B-cell malignancies.
- Tislelizumab: An anti-PD-1 antibody for the treatment of various types of cancer.
Collaborations and Partnerships[edit]
BeiGene has entered into several strategic collaborations and partnerships with leading pharmaceutical companies to advance its drug development programs. These partnerships include collaborations with companies such as Celgene, Amgen, and Novartis.
Stock Market[edit]
BeiGene is publicly traded on the NASDAQ under the ticker symbol BGNE and on the Hong Kong Stock Exchange under the ticker symbol 6160.
.png){kind=link}
